Krilogy Financial’s Vanda Pharmaceuticals VNDA Stock Holding History

Krilogy Financial’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-16,308	Closed	-$100K	–	1182
2026 Q2	$100K	Buy	+16,308	New	+$107K	﹤0.01%	1009
2018 Q4	–	Sell	-100	Closed	-$2K	–	662
2018 Q3	$2K	Buy	+100	New	+$2.04K	﹤0.01%	749
2017 Q3	–	Sell	-200	Closed	-$3K	–	848
2017 Q2	$3K	Hold	200	–	–	﹤0.01%	649
2017 Q1	$3K	Hold	200	–	–	﹤0.01%	635
2016 Q4	$3K	Buy	200 +100	+100%	+$1.61K	﹤0.01%	635
2016 Q3	$2K	Sell	100 -200	-67%	-$2.69K	﹤0.01%	677
2016 Q2	$3K	Hold	300	–	–	﹤0.01%	665
2016 Q1	$3K	Buy	+300	New	+$2.46K	﹤0.01%	589
2015 Q4	–	Sell	-300	Closed	-$3K	–	602
2015 Q3	$3K	Buy	+300	New	+$3.67K	﹤0.01%	524

Other funds holding VNDA

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Krilogy Financial's VNDA Position: Q3 2026 in Review

Krilogy Financial sold out of Vanda Pharmaceuticals (VNDA) in Q3 2026, closing a stake of 16,308 shares — an estimated $100K sold.

Krilogy Financial first reported a position in VNDA in Q3 2015 and held it in 9 quarters. The position peaked at $100K in Q2 2026. 19 funds tracked by Wall St. Rank hold VNDA as of Q3 2026.

Krilogy Financial reported no remaining Vanda Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
Krilogy Financial sold 16,308 Vanda Pharmaceuticals shares in Q3 2026, an estimated $100K.
Krilogy Financial first reported a position in Vanda Pharmaceuticals in Q3 2015 and held it in 9 quarters.
Krilogy Financial's Vanda Pharmaceuticals position peaked at $100K in Q2 2026.
19 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2026.

Based on Krilogy Financial's 13F filing for Q3 2026, filed 13 Oct 2026.